secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2022-09-02T23:59:59+00:00
Accession:  0001640334-22-001913
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience appoints Catherine Turkel to board; grants stock options, receives Mexican patent
--------------------------------------------------------------------------------

- Appointed Catherine Turkel, PharmD, PhD as independent director; board expanded to six members effective Sept 2, 2022.
- Dr. Turkel brings 20+ years pharma exec experience; led Allergan's BOTOX Chronic Migraine registration program.
- Compensation set parallel to other independent directors; contributes to drug development and Nasdaq diversity goals.
- Granted 103,500 options at $2.91 expiring Aug 2027 to employees/directors/officers; 3,400 options at $3.04 expiring Sep 2027 to a director.
- Awarded Mexican patent #390001 for stable ready-to-drink lipophilic active agent beverage compositions (grant date Feb 10, 2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001913/0001640334-22-001913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001913/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-001913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer